Pregabalin induced balance disorder, asthenia, edema, and constipation in an elderly adult: A case report.

Adverse drug reaction Case report Dose-dependent AEs Pregabalin The elderly population

Journal

World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806

Informations de publication

Date de publication:
16 Jun 2023
Historique:
received: 07 12 2022
revised: 03 02 2023
accepted: 31 03 2023
medline: 30 6 2023
pubmed: 30 6 2023
entrez: 30 6 2023
Statut: ppublish

Résumé

Pregabalin is widely used to treat neuropathic pain associated with postherpetic neuralgia. To our knowledge, this is the first report on simultaneously occurring dose-related adverse drug reactions (ADRs) of balance disorder, asthenia, peripheral edema, and constipation in an elderly patient after pregabalin. A 76-year-old female with a history of postherpetic neuralgia was prescribed pregabalin (300 mg daily). After taking pregabalin for 7 d, the patient developed balance disorder, weakness, peripheral pitting edema (2+), and constipation. On days 8-14, the pregabalin dose was reduced to 150 mg/d based on creatinine clearance. The patient's peripheral edema improved significantly with the disappearance of all other adverse symptoms. On day 15, the pregabalin dose was increased to 225 mg/d to relieve pain. Unfortunately, the symptoms mentioned earlier gradually reappeared after 1 wk of pregabalin treatment. However, the complaints were not as severe as when taking 300 mg/d pregabalin. The patient consulted her pharmacist by telephone and was advised to reduce the dose of pregabalin to 150 mg/d and add acetaminophen (0.5 g, q6h) to relieve pain. The patient's ADRs gradually improved over the following week. Older patients should be prescribed a lower initial dose of pregabalin. The dose should be titrated to the maximum tolerable dose to avoid dose-limiting ADR. Dose reduction and the addition of acetaminophen may help limit ADR and improve pain control.

Sections du résumé

BACKGROUND BACKGROUND
Pregabalin is widely used to treat neuropathic pain associated with postherpetic neuralgia. To our knowledge, this is the first report on simultaneously occurring dose-related adverse drug reactions (ADRs) of balance disorder, asthenia, peripheral edema, and constipation in an elderly patient after pregabalin.
CASE SUMMARY METHODS
A 76-year-old female with a history of postherpetic neuralgia was prescribed pregabalin (300 mg daily). After taking pregabalin for 7 d, the patient developed balance disorder, weakness, peripheral pitting edema (2+), and constipation. On days 8-14, the pregabalin dose was reduced to 150 mg/d based on creatinine clearance. The patient's peripheral edema improved significantly with the disappearance of all other adverse symptoms. On day 15, the pregabalin dose was increased to 225 mg/d to relieve pain. Unfortunately, the symptoms mentioned earlier gradually reappeared after 1 wk of pregabalin treatment. However, the complaints were not as severe as when taking 300 mg/d pregabalin. The patient consulted her pharmacist by telephone and was advised to reduce the dose of pregabalin to 150 mg/d and add acetaminophen (0.5 g, q6h) to relieve pain. The patient's ADRs gradually improved over the following week.
CONCLUSION CONCLUSIONS
Older patients should be prescribed a lower initial dose of pregabalin. The dose should be titrated to the maximum tolerable dose to avoid dose-limiting ADR. Dose reduction and the addition of acetaminophen may help limit ADR and improve pain control.

Identifiants

pubmed: 37388795
doi: 10.12998/wjcc.v11.i17.4060
pmc: PMC10303619
doi:

Types de publication

Case Reports

Langues

eng

Pagination

4060-4064

Informations de copyright

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: All authors declare that they have no conflicts of interest.

Références

Pain Pract. 2005 Jun;5(2):95-102
pubmed: 17177755
Drugs. 2004;64(24):2813-20; discussion 2821
pubmed: 15563250
Pharmacopsychiatry. 2009 Mar;42(2):75-6
pubmed: 19308883
Pain Pract. 2015 Jan;15(1):47-57
pubmed: 24279736
J Pain Res. 2015 Jun 29;8:303-9
pubmed: 26170712
Postgrad Med. 2017 Nov;129(8):921-933
pubmed: 28967801
Pain Res Manag. 2014 Nov-Dec;19(6):e164-7
pubmed: 24945288
Epilepsia. 2011 Apr;52(4):826-36
pubmed: 21320112
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508

Auteurs

Li-Ping Ma (LP)

Office of Clinical Trial Institution, Peking University Shougang Hospital, Beijing 100144, China.

Cheng Wen (C)

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.

Tong-Xiang Zhao (TX)

Office of Clinical Trial Institution, Peking University Shougang Hospital, Beijing 100144, China.

Xiang-Ming Jiang (XM)

Office of Clinical Trial Institution, Peking University Shougang Hospital, Beijing 100144, China.

Jin Gu (J)

Department of Gastrointestinal Surgery, Peking University Shougang Hospital, Beijing 100144, China. applemary18@163.com.

Classifications MeSH